-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Chemed, Raises Price Target to $590

Benzinga·07/31/2026 16:08:08
语音播报
Oppenheimer analyst Michael Wiederhorn maintains Chemed (NYSE:CHE) with a Outperform and raises the price target from $500 to $590.